An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

To accelerate discovery, scientists from ATCC and the Broad Institute collaborated to engineer a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...

Researchers at Linköping University show how two important cancer-related proteins can be prevented from collaborating with each other.

For decades, men have had limited options when it comes to birth control, with little innovation since the late 20th century.

While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Senhwa Biosciences raises $16M to advance AI-powered drug discovery, accelerate cancer treatment trials, and expand machine ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.